The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
The latest on manufacturing and potential treatments for COVID-19 with news from Pfizer, J&J, Gilead Sciences, Genentech, Inovio, and Glenmark.
US DOJ OKs Info-Sharing on mAb Mfg Among Pharma Companies The US Department of Justice (DOJ) says...
Sanofi and GlaxoSmithKline (GSK) have reached an agreement, subject to a final contract, with the UK government for the supply of up to 60 million doses of a COVID-19 vaccine developed by Sanofi in partnership with GSK. The vaccine is based on...
Sandoz, the generics and biosimilars arm of Novartis, has announced a joint investment with the Austrian federal government for antibiotics manufacturing in Europe.
Sandoz intends to invest more than EUR 150 million ($178 million) over the next...
The US government, through the US International Development Finance Corporation (DFC), has signed a letter of interest to provide a $765-million loan to Eastman Kodak Company to support the launch of Kodak Pharmaceuticals, a new arm of the company...
Moderna, a clinical-stage biopharmaceutical company developing messenger RNA (mRNA) therapeutics and vaccines, will receive an additional commitment of up to $472 million from the Biomedical Advanced Research and Development Authority (BARDA), part...
AstraZeneca has entered into a global development and commercialization agreement with Daiichi Sankyo, in a deal worth up to $6 billion, for DS-1062, Daiichi Sankyo’s antibody drug conjugate (ADC) for treating multiple tumor types.
DS-1062 is in...
The latest on manufacturing and potential treatments for COVID-19 with news from AstraZeneca, CanSino Biologics, CGT Catapult, Bharat Biotech, and Celltrion.
AstraZeneca Reports Promising Early-Trial Results of COVID-19 VaccineAstraZeneca reports...
GlaxoSmithKline (GSK) and CureVac, a Tubingen, Germany-based clinical-stage biopharmaceutical company developing a messenger ribonucleic acid (mRNA) therapeutics, have signed a strategic collaboration agreement, in a deal worth up to £866 million...
Pfizer and BioNTech, a Mainz, Germany-based immunotherapy company, have entered an agreement with the US Department of Health and Human Services and the Department of Defense, in a deal worth up to $1.95 billion, to provide up to 600 million doses...
A roundup of news from Switzerland (BI, Numab Therapeutics) and the US (Bayer, Elanco, Mylan, Merck & Co, Dewpoint Therapeutics, and Nephron Pharmaceuticals).
Switzerland
BI, Numab Therapeutics in Pact for Antibody Therapies for Cancer,...
Roche and Blueprint Medicines, a Cambridge, Massachusetts-based biopharmaceutical company, have signed a licensing and collaboration agreement, in a deal worth up to $1.7 billion, to develop and commercialize pralsetinib, an investigational oral...
Belén Garijo, currently a member of Merck KGaA’s Executive Board, has been named Vice Chairman of the Executive Board and Deputy Chief Executive Officer (CEO) of Merck KGaA, effective July 13, 2020.
Belén Garijo joined Merck KGaA in 2011 as Chief...
Grifols, a healthcare company specializing in plasma medicines, has agreed to acquire a plasma fractionation facility and two purification facilities in Montreal and 11 US-based plasma-collection centers from GC Pharma (formerly Green Cross...
Gilead Sciences has agreed to acquire a 49.9% equity interest in Tizona Therapeutics, a South San Francisco, California-based company developing cancer immunotherapies, for $300 million and has an exclusive option to acquire the remainder of Tizona...
Blackstone, a private investment firm, has closed on its first fund in the life sciences, Blackstone Life Sciences, with $4.6 billion in total capital commitments.
The fund is focused on three main investment strategies: strategic collaborations...
